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Adjuvant Therapy for Early Uterine
High-Grade Leiomyosarcoma
TO THE EDITOR:
The article by Hensley et al1 recently published in
Journal of Clinical Oncology was interesting, even if
apparently negative (Gynecology Oncology Group
[GOG]-0277 randomized phase III trial). The study
investigated the activity and safety of gemcitabine
plus docetaxel followed by doxorubicin versus
observation in patients with uterus-limited, high-
grade leiomyosarcoma (LMS) in an adjuvant setting.
Although the study was closed for accrual futility,
available survival results (disease-free survival, overall
survival) failed to show better outcomes in the ex-
perimental arm. This is probably, for different reasons,
the typical study that should not have been started or
completed. Adjuvant therapy for early-stage uterine
LMS remains controversial, and at themoment, cannot
be recommended.
In 2013, the French Sarcoma Group designed a
multicentric phase III study (SARCGYN protocol),
comparing adjuvant chemotherapy (doxorubicin plus
ifosfamide and cisplatin) followed by radiotherapy (RT)
versus RT alone in patients with localized uterine
LMS.2 This study was also closed for accrual futility,
but nevertheless, 81 patients were randomly assigned
in 19 institutions (39 in the chemotherapy plus RT
group and 42 in the RT-alone group). In the trial by
Hensley et al,1 only 38 patients from 701 international
centers, in 4 years of recruitment, were enrolled and
randomly assigned. Although early uterine LMS is an
extremely rare neoplasm, it is difficult to understand
how such a low accrual could have occurred in such
a large number of centers. It is even more difficult
to understand why the study was not interrupted
much earlier. It is probable that the reason for such a
low accrual is a result of the absence of an active
treatment in the control arm, as suggested by the
authors.
An important reason for this poor recruitment could
be because of the difficulty of coordinating and
monitoring such a large number of participating
centers. However, in 2009, a European Organisation
for Research and Treatment of Cancer (EORTC)
randomized trial from 36 institutions evaluated the
role of adjuvant pelvic RT versus observation (no
active treatment in the control arm) for the treatment
of stage I and II uterine sarcomas.3 In this study, 103
patients with LMS, 91 patients with carcinosarcoma,
and 28 patients with endometrial stromal sarcoma
were enrolled over 13 years of recruitment. No
difference in either overall or disease-free survival
was observed for LMS. Therefore, the absence of an
active treatment in the control arm cannot be the only
cause of the poor enrollment in the study by Hensley
et al,1 even if the choice of simple observation seems
unacceptable. However, in our opinion, other as-
pects of the study deserve careful evaluation and
discussion.
Observing the patient characteristics in Table 1 in the
article, it is evident that there is a certain non-
homogeneity regarding the age of the patients en-
rolled. As many as 80% of the patients enrolled in the
experimental arm were younger than 60 years of age
versus 20% who were older than 60 years of age.
Considering also that in the experimental arm, there
were five deaths compared with one in the control
group, it is evident that the risk of death linked to an
active treatment may be higher in older patients,
further strengthening the belief that the proposed
therapeutic schedule in this study may be potentially
risky, mostly in patients deemed physically fragile. This
opinion is also supported by the evidence that 11
patients (47%) in the chemotherapy arm experienced
at least one grade 3 or 4 adverse event compared with
one patient in the observation arm who experienced
grade 3 hypertension.
The authors of the GOG-0277 study concluded that
their results “do not support the use of adjuvant
gemcitabine plus docetaxel followed by doxorubicin
for uterus-limited, high-grade LMS.”1 In our opinion, it
is difficult to fully share this conclusion. It is also risky to
say that this is a definitively negative study; there are
too many limitations and biases. With much larger
trials, with a better selection of patients, with a more
suitable and attractive control group, and with the use
of novel agents,4 we could perhaps obtain positive
results in the next studies with adjuvant therapy of this
rare tumor.
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